% | $
Quotes you view appear here for quick access.

Pfizer Inc. Message Board

  • jrzbiz jrzbiz Jun 29, 2014 7:46 PM Flag

    PFE buyout of MNKD makes way more sense that the bid they made for AstraZ

    Pfizer is the leading pain management seller, and big stakes in the vaccine markets, and can get back in an improved and popular inhaled insulin approval by FDA. Pfizer's approved drugs delivered through Technosphere inhaled platform would make them very very wealthy! Let's see if PFE is smart enough to go after MNKD before they miss out. MNKD inhalable technology is a real threat to PFE sales, but they could be a big positive for their sales with a partner or buyout with MNKD.

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • Let them buy BMY at $60


      You are ignorant of history. PFE dumped inhaled insulin at a humongous cost once, why would they make the same mistake twice

      • 2 Replies to u_r_a_weird_wacko
      • LONDON, Aug 2 (APM) - Novo Nordisk said on Wednesday it was suing Pfizer in a bid to
        stop the U.S. group marketing its inhaled insulin, Exubera.
        In a statement, the Danish group said: "On 1 August Novo Nordisk filed a lawsuit against
        Pfizer claiming that Pfizer's product Exubera infringes Novo Nordisk's patents covering
        inhaled insulin treatment for diabetes.
        "The lawsuit, filed in United States Federal Court in the Southern District of New York,
        alleges that Pfizer wilfully and deliberately infringed the patents."
        General Council for Novo, Ole Ramsby, told APM the lawsuit included a motion for a
        preliminary injunction to stop Pfizer marketing Exubera in the U.S.
        "We expect a decision (from the court) in a couple of weeks. We do expect to win the
        injunction. We think we can demonstrate a clear infringement by Pfizer," the lawyer said.
        Ramsby said Novo holds five patents related to inhaled insulin which give intellectual
        protection to 2013. The patents come from Novo's long-term partnership with California
        biotech, Aradigm, and Pfizer has broken all five, he added.
        The Danish company's rival inhaled insulin is still in Phase III trials and Ramsby could not
        say when it will be launched. However, he said the result of being second to market in the
        U.S. after Pfizer were grave.
        "Every customer on Exubera is a customer lost to us ... we will suffer irreparable harm if the
        injunction is not granted."
        Asked why Novo had taken so long to take legal action, Ramsby said that for legal reasons
        the company had to wait until Pfizer began telling physicians about its new product.
        Nobody from Pfizer was immediately available to comment.
        Exubera, which Pfizer acquired from Sanofi-Aventis, was recently launched in Germany, its
        first major EU market, and is set to be rolled out in the United States in September.
        The world's first inhaled insulin is one of the key products that Pfizer is relying on for
        continued growth followin

      • No Pfizer CEO will ever touch inhaled insulin after the Exubra fiasco.

34.77-0.05(-0.14%)Aug 25 4:00 PMEDT